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Abstract
Background: Malignant melanoma metastasis to the breast is a rare disease.
Case presentation: We present the case of a 58-year-old postmenopausal Caucasian woman with metastatic
malignant melanoma of unknown origin of the right breast. She presented with a palpable lump in the inferior
quadrant of her right breast. The investigations concluded it was breast metastasis from a malignant melanoma of
unknown origin. The treatment consisted of mastectomy and axillary lymph node dissection. Two lymph nodes were
positive for tumor cells and one showed extracapsular extension. Our patient did not receive immediate adjuvant
therapy. Six weeks after the surgery, our patient presented a relapse in the right axilla (a 6 × 4 cm mass)
with positive internal mammary lymph nodes and a single brain metastasis. This relapse motivated an
adjuvant treatment with partial regression of the disease. Currently, our patient presents multiple metastases
with poor prognosis.
Conclusions: From this experience, we advocate an immediate aggressive handling of melanoma metastasis
to the breast.
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Background
The worldwide incidence and mortality rate of malignant
melanoma have been constantly increasing over the past
50 years in fair-skinned populations. Melanoma is the
fourth most frequent cancer in Switzerland. Its incidence
rate in Switzerland is one of the highest in Europe
with 24.6 out of 100,000 [1]. Approximately 20% of
malignant melanomas will metastasize, whether by
hematogenic or lymphatic route. The breast is a rare site
of metastases for extramammary tumors (incidence
1.3–2.7%) [2]. Malignant melanoma is the most common
cancer to metastasize to the breast. Therefore, in patients
with a history of malignant melanoma, the possibility
of a metastasis should be included in the differential
diagnosis.
Establishing the diagnosis can be difficult. Clinical
examination and imaging techniques are not specific.
Cytological and pathological examinations, with the help
of immunohistochemical stainings, are the key to the
diagnosis. In most cases, treatment consists of surgical
resection. The need for chemo-, radio- or immunotherapy
is case-dependent.
Finally, we would like to underline that this disease
can have a very aggressive course, as was the case with
our patient.
Case presentation
We present here the case of a 58-year-old postmeno-
pausal Caucasian woman with metastatic malignant
melanoma of unknown origin of the right breast. The
patient came to our emergency department in December
2014 after noticing a lump in her right breast. Upon
physical examination, a well-circumscribed mass of 2 cm
was confirmed in the lower external quadrant with no
skin involvement and no enlarged lymph nodes. A
thorough examination of the skin revealed no other
lesion. The patient had no previous history of malignant
melanoma or of removal of suspect skin lesion.
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The mammography and sonography examinations
showed an oval 16 × 10 × 13 mm, well-delimited hyper-
vascular mass, parallel to the skin (Fig. 1a). Our patient
underwent sonographically guided core biopsies. The
microscopic examination showed a poorly differentiated
tumor with medium to large cells with eosinophilic cyto-
plasm and pleomorphic nuclei. The immunohistochemis-
try evaluation was negative for estrogen and progesterone
receptors, as well as for E-cadherin and HER-2. It was
positive for protein S-100 and vimentin, therefore compat-
ible with the diagnosis of malignant melanoma. The KI-67
was 100%.
A magnetic resonance imaging (MRI) scan revealed a
3 cm lesion with no cutaneous or pectoral infiltration
(Fig. 1b) and a positron emission tomography-computed
tomography (PET-CT) scan showed a hypermetabolic
mammary mass with a homolateral metastatic axillary
adenopathy.
The case was presented to the multidisciplinary tumor
board of our referent tertiary center. It was decided to
repeat the biopsies in order to confirm the diagnosis.
Thus, our patient underwent a second biopsy of the
breast lesion and of the axillary adenopathy (5 February
2015) seen on the PET-CT scan. The diagnosis of
metastatic malignant melanoma of unknown origin with
positive axillary ipsilateral adenopathies was confirmed.
Our patient underwent a mastectomy with axillary
lymph node dissection in March 2015. The histopatho-
logical examination found a 4.5 × 4 × 3.9 cm mass, with
tumor-free margins: 0.4 cm of the cranial plane and 0.35
cm of the deep plane (Fig. 2a). The tumor cells were of
medium size with hyperchromatic nuclei and anisokar-
yosis. Some of the cells showed a large and eosinophilic
cytoplasm. The immunohistochemistry examination was
positive for protein S-100 and negative for Melan-A and
HMB-45. Other immunohistochemical markers were
tested for and were negative: epithelial markers (pancy-
tokeratin, Ber-EP4, p63, keratin 903, keratin 5/6, keratin
8/18), muscular markers (actin, desmin, caldesmon),
lymphohistiocytic markers (CD68 [KP1], PGM1, CD1a,
CD4, CD43, CD45), endothelial markers (CD31 and
CD34). The c-Kit was also negative (Fig. 2b and c).
Molecular biology sequencing showed no mutations
for KRAS gene (exons 2-5), NRAS gene (exons 2-5) and
BRAF gene (exon 15).
From the axillary lymph node dissection, 17 lymph
nodes were excised, of which two were positive for
tumor cells and one presented extracapsular extension.
Our patient underwent a complete dermatological, oph-
thalmological, ENT, gynecological and gastroenterological
(colonoscopy and gastroscopy) examination without
finding a primary lesion. A cerebral MRI scan did not
show any primary lesion or metastases. Our patient
did not receive adjuvant therapy, according to the de-
cision of the multidisciplinary tumor board of the ref-
erent tertiary center.
Six weeks later, our patient presented with a palpable
mass in the right axilla. At the sonographic examination, a
hypervascular 6 × 4 cm mass was visualized with a satel-
lite nodule of 1.6 × 1.2 cm, both of which were biopsied.
The results showed the same histologic and immunohisto-
chemical characteristics of the breast tumor, with a diffuse
nuclear and cytoplasmic S-100 expression. An MRI scan
(28 May 2015) (Fig. 3a and b) confirmed the right axillary
polylobulated 9 × 5 × 7 cm mass, in the pectoralis minor
muscle with thoracic wall infiltration, as well as a satellite
nodule of 2.7 cm and a single brain metastasis (Fig. 3c). A
complementary PET-CT scan (3 June 2015), showed a
hypercaptation at the site of the mastectomy with invasion
of the pectoralis major muscle, as well as a hypercaptation
in the right axilla and in the internal mammary lymph
nodes. There was no hepatic, pulmonary, adrenal, or
osseous dissemination
Our patient was referred to the tertiary center, and
mid-June, a treatment combining stereotaxic irradiation
of the brain metastasis and adjuvant therapy with ipilu-
mimab was initiated. At the end of August, the control
cerebral MRI and PET-CT scans showed the partial
Fig. 1 a Initial mammography. Well-delimited mass in the lower external quadrant of the right breast. b Initial magnetic resonance imaging.
Mass in the lower external quadrant of 2.8 × 3.0 × 3.0 cm. From the subcutaneous plane to the pectoral plane with no infiltration of the pectoral muscle.
Central necrosis with peripheral contrast enhancement
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regression of the brain metastasis. The right axillary
mass was decreased in size.
Discussion
Approximately 20% of malignant melanomas will
metastasize, whether by hematogenous or lymphatic
route. The incidence of breast metastases from extra-
mammary tumors varies between 1.3 and 2.7% [2].
According to a review of the literature by Koch et al. [3],
malignant melanoma is the most common cancer to
metastasize to the breast (29.8%). Other cancers known
to metastasize to the breast are: lung cancer (16.4%),
gynecological cancers with a majority of ovarian cancers
(12.7%), digestive tumors (9.9%), leukemia and lymphomas
(8.4%), sarcomas (7.3%), and renal tumors (1.5%). Malig-
nant melanoma can also occur as a primary intramam-
mary tumor [4].
In 70% of the cases, the patients are premenopausal
[2]. The lesions are mostly found in the upper external
quadrant [5]. In this particular situation, our patient was
Fig. 3 a and b Relapse magnetic resonance imaging. Right axillary mass in the right pectoralis minor muscle, in contact with the thoracic wall.
Satellite nodule in contact with the superior and inferior poles. Tumoral nodule in the mastectomy site. Right axillary and internal mammary adenopathies
Fig. 2 a Macroscopy of the tumor. The cut section of the breast tumor is nodular, tan to gray and more or less well-demarcated. b Standard
histology. The tumor cells are very anisokaryotic with abundant eosinophilic cytoplasm and numerous often atypical mitoses (hematoxylin and eosin (H&E), ×40).
c Immunohistochemistry. All tumor cells are strongly immunoreactive for S-100 in the cytoplasm and in the nuclei (S-100, ×40)
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a postmenopausal woman and the lesion was situated in
the inferior external quadrant.
Diagnosis
The diagnosis of malignant melanoma of the breast
can be challenging. The sonographic and mammo-
graphic findings of metastatic nodules are very diverse
and cannot be used to differentiate between a metas-
tasis and a primary mammary adenocarcinoma. A
metastatic nodule may even mimic a benign lesion
radiographically. It has been reported in the literature
that on mammography, metastatic nodules appear as
well defined opacities without calcifications. Sonogra-
phically, nodules are well-defined, round or oval, and
hypoechogenic with a well-defined posterior wall [5, 6].
The only finding that can differentiate it from a benign
nodule is the increased vascularity of the lesion [7], as in
this situation.
The key element in establishing the diagnosis of
malignant melanoma of the breast is the histopathological
examination combined with immunohistochemistry
staining techniques. The melanoma cells’ appearance and
architectural disposition are very diverse. Hematoxylin
and eosin (H&E) sections cannot be complete without
immunohistochemistry. No immunohistochemistry marker
is 100% specific or sensitive. The protein S-100 is a very
sensitive marker for melanoma (expressed in 95% of
tumors) but it is not specific and should be used in combin-
ation with others markers such as Melan-A, HMB-45 and
tyrosinase, which are much more specific (present in 70%
of melanomas). Moreover, melanomas can express other
markers such as CD31, CD68, epithelial membrane antigen,
and CAM5.2 [8]. In this case, the markers expressed
were protein S-100 and vimentin.
Staging and prognosis of melanoma and metastatic
melanoma of unknown primary origin (MUP)
Staging of melanoma in this particular case is challen-
ging since the tumor presented itself as a melanoma
metastasis as well as positive lymph nodes without a
detectable primary lesion. Regarding the anatomic stage
groupings for cutaneous melanoma (clinical and patho-
logic staging), this case should be considered at least a
stage III (Any T, ≥N1, M0), or even a stage IV (Any T,
any N, M1; M1a: metastases to skin, subcutaneous, or
distant lymph nodes) [9, 10]. By convention, the ana-
tomic staging should be used after complete excision of
the primary lesion, which was not feasible in this
situation, since the primary lesion was unknown.
An ongoing debate exists in the literature regarding
the difference in prognosis when comparing metastatic
melanoma of unknown primary origin (MUP) and
metastatic melanoma of known primary origin (MKP)
[11]. Some studies show a better prognosis when the
primary lesion is unknown (with the same correspond-
ing tumor stage) [12]. Other authors conclude that
MUP patients with nodal metastases have a similar
survival, compared with MKP stage III patients with
macroscopic involvement, and that MUP patients with
distant metastases have a similar survival as MK stage
IV patients [13].
As mentioned before, in MUP patients, the staging is
difficult as it is hard to distinguish which patient has a
regional or a distant (sub)cutaneous or nodal metastasis.
Therefore, the prognosis is difficult to establish [13].
Nonetheless, the management of MUP patients should
be the same as those with stage-matched MKP [11].
Surgical treatment
The main treatment of malignant melanoma is wide
excision with free margins combined with sentinel node
biopsy. Lymph node resection should also be performed
if axillary node involvement is positive. Mastectomy
and internal mammary node dissection are not recom-
mended currently [4].
Our patient underwent mastectomy and axillary node
dissection as a positive lymph node was confirmed by
biopsy.
Adjuvant radiotherapy (RT)
There is no consensus on the use of adjuvant radio-
therapy after lymph node dissection in malignant
melanoma, but it has been recently shown in a phase III
trial that RT could decrease the rate of local recurrence,
following surgery. The trial showed, however, that there
was no impact on overall survival. There was a reduction
of 52% of lymph node field relapse in patients who had
undergone radiotherapy, but no differences for the
relapse-free survival (70 vs. 73 relapses, hazard ratio [HR]
0.91, 95% confidence interval [CI] 0.65–1.26; p = 0.56) or
overall survival (59 vs. 47 deaths, HR 1.37, 95% CI 0.94–
2.01; p = 0.12).
In our case, the patient had extranodal spread and did
not receive adjuvant radiotherapy. A lymph-node field
relapse occurred 6 weeks after the surgery with a mass
of 9 × 5 × 7cm with a satellite nodule of 2.7 cm [14].
INF-α, chemotherapy and immune vaccines
INF (interferon)-α is the standard of care in selected
high-risk patients with stage III [9]. High doses of INF-α
2b have been proved, in clinical trials, to have a benefi-
cial effect on distant disease-free survival, but not on
overall survival [15]. The mechanism by which it targets
melanoma cells is not fully understood. It has been
shown to downregulate MEK/ERK MAPK, an important
pathway of cell metastasis as well as STAT3, another
pathway for cell survival, metastasis, proliferation, angio-
genesis, and immune evasion.
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Chemotherapy has not shown any beneficial effect on
either distant-free survival or overall survival, whether it
is used as a single agent or in combination with other
chemotherapeutics, hormonal or biological therapy.
Chemotherapeutic agents include dacarbazine and hy-
droxyurea [15].
Immune vaccines tend to activate an antitumor re-
sponse by cytotoxic T cell response. In the case of mel-
anoma, specific melanoma antigens are incorporated
(MART1/Melan-A, gp100, tyrosinase), which should be
potentially recognized by cytotoxic T lymphocytes. The
patients who responded to any of the peptides and de-
veloped a T cell response showed survival times that
were doubled compared to those who did not respond.
Other antigens have been evaluated with no survival
benefits, some are even suspected to have induced im-
munosuppression [16].
New therapies
A better understanding of the immune system modula-
tion and of the genetic mutations underlying melanoma
cells has led to the development of new agents.
These agents attack melanomas through two different
pathways: (1) by modulating the immune system to target
melanoma cells or (2) by altering the cell cycle of
melanoma cells with oncogene-targeted therapies [17, 18].
Through immune-modulating antibodies (anti-CTLA4,
anti-PD1, anti-CD40, anti-CD137, and anti-OX40), an
antitumor immune response is created. One of those
immune-modulating antibodies is the anti-CTLA4
antibody ipilimumab (IgG1). The CTL4 antigen is a
checkpoint that downregulates T cell activation and
proliferation. The antibody targets, and therefore
blocks, the CTL4 antigen, resulting in an upregulation
of T cell activation and proliferation.
Two phase III studies showed the superiority of this
treatment compared to dacarbazine and peptide vac-
cines. Ipilimumab reduces the risk of recurrence by 20%
with an overall survival that is stable and sustainable at
3 years [17, 18]. On the other hand, targeted therapies
block specific pathways or specific mutated oncogenes.
Known oncogenic activating mutations are: BRAF, c-KIT
and NRAS.
BRAF, for example, is known for its activating muta-
tion V600E, an important actor for the proliferation of
melanoma cells. Vemurafenib is a BRAF inhibitor that
offers overall and progression-free survival [19]. It has
been approved by the Food & Drug Agency (FDA) for
the treatment of unresectable metastatic melanoma.
Unfortunately, although the initial response is very high,
the tumor develops mechanisms of resistance against
these drugs. Instead, multiple pathways should be
targeted in order to achieve a successful therapy [18].
It seems that the molecular status of the melanoma at
the time of the histological diagnosis needs to be deter-
mined, so that each patient can be treated individually
according to the specificities of the melanoma [18].
Conclusions
Malignant melanoma of the breast, whether primary or
metastatic, is a particularly rare and aggressive disease.
It is of primary importance to make an early diagnosis
and immunohistochemistry plays a major role. The
treatment consists of adequate resection. Adjuvant ther-
apy is not mandatory, but should be started without
delay, if found necessary, as relapse can occur in a very
short period of time.
This case has shown a very aggressive course of the
disease with fast locoregional relapse and emergence of
distant metastases. It outlines the difficulty in the assess-
ment of the need of adjuvant therapy. From this experi-
ence, we advocate an immediate aggressive handling of
melanoma metastasis to the breast.
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